Evotec receives $23.8 million grant to join the global fight against TB

• The Bill & Melinda Gates Foundation Supports Evotec With A $ 23.8 M Grant To Generate Critical Data For Selecting Best Drug Combinations For Phase II Clinical Trials
• Tuberculosis Is The Leading Cause Of Death Due To An Infectious Disease Worldwide
• Five-Year Partnership Is Focused On Evaluating New Treatment Regimens That Can Substantially Reduce Treatment Time And Overcome Resistance To Current Therapies

HAMBURG, GERMANY, June 10, 2019 /Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis ("TB"), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide. The current standard treatment regimen for TB consists of a minimum of 6 months of treatment with 4 drugs administered under direct observation, but treatment is much longer when TB is drug resistant.